Veracyte, inc. (VCYT)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Total Revenue

120,368

92,008

71,953

65,085

49,503

38,190

21,884

11,628

2,645

Operating expenses:
Cost of testing revenue

36,077

33,078

28,195

25,462

21,497

16,606

12,607

7,584

2,925

Cost, Direct Material

446

0

0

-

-

-

-

-

-

Research and development

14,851

14,820

13,881

15,324

12,796

9,804

7,810

6,608

6,680

Selling and marketing

53,691

41,313

32,260

28,248

25,293

21,932

12,540

8,447

2,934

General and administrative

29,029

23,963

23,088

23,787

22,583

18,854

12,100

7,918

5,372

Intangible asset amortization

1,401

1,067

1,067

1,067

800

0

-

-

-

Total operating expenses

135,495

114,241

98,491

93,888

82,969

67,196

45,057

30,557

17,911

Loss from operations

-15,127

-22,233

-26,538

-28,803

-33,466

-29,006

-23,173

-18,929

-15,266

Interest income

-

-

-

-

-

-

-

-

2

Interest expense

677

1,963

4,941

2,757

378

439

233

-

-

Other income, net

3,205

1,197

476

202

140

72

-2,174

280

819

Net loss and comprehensive loss

-12,599

-22,999

-31,003

-31,358

-33,704

-29,373

-25,580

-18,649

-14,445

Comprehensive loss

-12,599

-22,999

-31,003

-31,358

-33,704

-29,373

-25,580

-18,649

-

Net loss per common share, basic and diluted (in usd per share)

-0.27

-0.62

-0.91

-1.09

-1.30

-1.36

-6.15

-28.68

-24.90

Shares used to compute net loss per common share, basic and diluted (in shares)

46,138

37,020

33,925

28,830

25,994

21,639

4,158

650

580

Testing
Total Revenue

107,355

91,058

71,953

-

-

-

-

-

-

Product
Total Revenue

923

0

0

-

-

-

-

-

-

Biopharmaceutical
Total Revenue

8,090

950

0

-

-

-

-

-

-

Collaboration revenue
Revenue from Contract with Customer, Excluding Assessed Tax

4,000

0

0

-

-

-

-

-

-